{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"1510.0","value":"146.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 30 MINUTES"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.1","upperLimit":"1570.0","value":"487.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 1 HOUR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.2","upperLimit":"826.0","value":"353.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"774.0","value":"192.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 4 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"337.0","value":"87.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 8 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.4","upperLimit":"1220.0","value":"231.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"CYCLE 1 DAY 4, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.1","upperLimit":"988.0","value":"246.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"557.0","value":"142.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.5","upperLimit":"1250.0","value":"390.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 30 MINUTES"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.8","upperLimit":"1640.0","value":"448.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 1 HOUR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"153.0","upperLimit":"1290.0","value":"444.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.8","upperLimit":"881.0","value":"247.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 4 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"756.0","value":"154.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 8 HOURS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of Nirogacestat when administered orally in combination with belantamab mafodotin.","dispersionType":"Full Range","groups":[{"description":"In CE Phase, Participants with RRMM received 0.95 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 3 weeks (Q3W), infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.","reportingStatus":"POSTED","timeFrame":"PRE-DOSE (PD), Post-dose 30 Minutes, 1H, 2H, 4H, 8H on C1D1; PD on C1D4 and D8 ; PD, Post-dose 30 Minutes, 1H, 2H, 4H, 8H on C2D1","title":"CE Phase: Plasma Concentration of Nirogacestat When Administered in Combination With Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"ng/mL"}